Maybe a cheap takeover or they may delist and go private.
Currently we’re holding more cash than our valuation
and that does not include the potential for PBT2 for antibiotic resistance.
A lot of upside here especially if there is movement on the PBT2 front.
Good luck to all the suffering long term holders.
Ann: First Patient Enrolled in Australia in global Phase 2 Trial, page-15
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $23.94M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $508 | 124.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 103 | 97947018 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179262 | 15 |
View Market Depth
| Last trade - 11.42am 25/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |